Gossamer Bio (NASDAQ:GOSS) Earns Overweight Rating from Analysts at Barclays

Barclays began coverage on shares of Gossamer Bio (NASDAQ:GOSS) in a research report report published on Tuesday, MarketBeat.com reports. The brokerage issued an overweight rating and a $9.00 price objective on the stock.

Other research analysts have also issued research reports about the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Gossamer Bio in a research report on Thursday, January 22nd. HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of Gossamer Bio in a research report on Thursday, January 22nd. Finally, Wall Street Zen cut Gossamer Bio from a “hold” rating to a “sell” rating in a report on Friday, January 23rd. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $8.60.

Gossamer Bio Price Performance

GOSS stock opened at $2.42 on Tuesday. Gossamer Bio has a one year low of $0.76 and a one year high of $3.87. The stock has a market cap of $560.13 million, a price-to-earnings ratio of -3.51 and a beta of 1.92. The company has a fifty day moving average price of $3.06 and a two-hundred day moving average price of $2.62.

Gossamer Bio (NASDAQ:GOSS) last issued its quarterly earnings data on Wednesday, November 5th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.02). The company had revenue of $13.29 million during the quarter, compared to the consensus estimate of $6.32 million. Gossamer Bio had a negative net margin of 354.50% and a negative return on equity of 1,774.72%. Research analysts anticipate that Gossamer Bio will post -0.28 EPS for the current fiscal year.

Institutional Trading of Gossamer Bio

Several institutional investors and hedge funds have recently modified their holdings of the business. Bank of America Corp DE grew its position in Gossamer Bio by 107.2% in the fourth quarter. Bank of America Corp DE now owns 84,788 shares of the company’s stock valued at $77,000 after acquiring an additional 43,866 shares during the last quarter. Invesco Ltd. bought a new position in shares of Gossamer Bio in the first quarter worth about $48,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Gossamer Bio in the 1st quarter valued at approximately $213,000. Goldman Sachs Group Inc. grew its holdings in shares of Gossamer Bio by 720.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 939,603 shares of the company’s stock valued at $1,034,000 after purchasing an additional 825,047 shares during the last quarter. Finally, Jane Street Group LLC increased its position in Gossamer Bio by 5,250.1% during the 1st quarter. Jane Street Group LLC now owns 683,423 shares of the company’s stock worth $752,000 after purchasing an additional 670,649 shares in the last quarter. 81.23% of the stock is currently owned by institutional investors.

Gossamer Bio Company Profile

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.